EIF2AK3 and breast carcinoma: In this study, we used various types of cancer cells to verify whether the activation of the PERK/eIF2α axis is a general phenomenon under taxanes treatment and further explored the role of PERK/eIF2α axis in PTX resistance by using the PTX-resistant breast cancer cells.